Get started
Author

Michal Kwiatek

OpenAlex ID: A5148624000
Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial
2026 · Prithviraj Bose, Haris Ali, et al. · Journal of Clinical Oncology · 4
IBCL-1332: Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab With Lenalidomide and Rituximab vs Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
2026 · Bradley D Hunter, Lorenzo Falchi, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-142: Golcadomide—A Potential First-in-Class Oral CELMoD Combined With Pola-R-CHP in Frontline Aggressive B-Cell Lymphoma: Safety and 12-Month Efficacy
2026 · Muhamad Alhaj Moustafa, Theodoros Vassilakopoulos, et al. · Clinical Lymphoma Myeloma & Leukemia
CLL-796: Pirtobrutinib in Treatment-Naïve Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Pooled Results From BRUIN CLL-313 and BRUIN CLL-314
2026 · William GWierda, Wojciech Jurczak, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-429: Daybreak CLL-201: A Study of Bexobrutideg (NX-5948), a Bruton Tyrosine Kinase Degrader, in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Treated With a Covalent BTK Inhibitor, a Noncovalent BTK Inhibitor, and a BCL2 Inhibitor
2026 · Michael Tees, Paolo Ghia, et al. · Clinical Lymphoma Myeloma & Leukemia
CLL-427: Updated Efficacy and Safety Data From an Ongoing Phase 1a/b Trial of the Bruton's Tyrosine Kinase Degrader Bexobrutideg (NX-5948) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Across Lines of Therapy
2026 · Zulfa Omer, Talha Munir, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-796: Pirtobrutinib in Treatment-Naïve Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Pooled Results From BRUIN CLL-313 and BRUIN CLL-314
2026 · William G Wierda, Wojciech Jurczak, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma
2026 · Lorenzo Falchi, Marcel Nijland, et al. · Clinical Lymphoma Myeloma & Leukemia
ORAL ABSTRACT: IBCL-1332: Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab (E) With Lenalidomide and Rituximab (R2) Versus R2 for Relapsed or Refractory Follicular Lymphoma (R/R FL)
2026 · Bradley D Hunter, Lorenzo Falchi, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-1332: Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab With Lenalidomide and Rituximab vs Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
2026 · Bradley D Hunter, Lorenzo Falchi, et al. · Clinical Lymphoma Myeloma & Leukemia
CLL-429: Daybreak CLL-201: A Study of Bexobrutideg (NX-5948), a Bruton Tyrosine Kinase Degrader, in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Treated With a Covalent BTK Inhibitor, a Noncovalent BTK Inhibitor, and a BCL2 Inhibitor
2026 · Michael Tees, Paolo Ghia, et al. · Clinical Lymphoma Myeloma & Leukemia
IBCL-1346: Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab in EPCORE FL-1 vs Real-World Chemoimmunotherapy in Relapsed/Refractory Follicular Lymphoma
2026 · Habte Yimer, Lorenzo Falchi, et al. · Clinical Lymphoma Myeloma & Leukemia
ABCL-142: Golcadomide—A Potential First-in-Class Oral CELMoD Combined With Pola-R-CHP in Frontline Aggressive B-Cell Lymphoma: Safety and 12-Month Efficacy
2026 · Muhamad Alhaj Moustafa, Theodoros Vassilakopoulos, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-427: Updated Efficacy and Safety Data From an Ongoing Phase 1a/b Trial of the Bruton's Tyrosine Kinase Degrader Bexobrutideg (NX-5948) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Across Lines of Therapy
2026 · Zulfa Omer, Talha Munir, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-1346: Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab in EPCORE FL-1 vs Real-World Chemoimmunotherapy in Relapsed/Refractory Follicular Lymphoma
2026 · Habte Yimer, Lorenzo Falchi, et al. · Clinical Lymphoma Myeloma & Leukemia
IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma
2026 · Lorenzo Falchi, Marcel Nijland, et al. · Clinical Lymphoma Myeloma & Leukemia
MPN-752: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase 3 SENTRY Trial
2026 · John Mascarenhas, Haris Ali, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MPN-752: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase 3 SENTRY Trial
2026 · John Mascarenhas, Haris Ali, et al. · Clinical Lymphoma Myeloma & Leukemia
Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial
2026 · Prithviraj Bose, Haris Ali, et al. · Journal of Clinical Oncology
PDF
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial
2026 · Umberto Vitolo, Juan Miguel Bergua Burgues, et al. · The Lancet Haematology
Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis: Phase 3 SENTRY trial.
2026 · John Mascarenhas, Haris Ali, et al. · Journal of Clinical Oncology
Pirtobrutinib in treatment-naïve patients with CLL/SLL: Pooled results from BRUIN CLL-313 and BRUIN CLL-314.
2026 · William G. Wierda, Wojciech Jurczak, et al. · Journal of Clinical Oncology
PDF
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, + Pola-RCHP in patients (pts) with newly diagnosed aggressive B-cell lymphoma (a-BCL): Safety and 12-month (mo) efficacy results.
2026 · Marc S. Hoffmann, Grzegorz S. Nowakowski, et al. · Journal of Clinical Oncology
Works count: 24
Citation count: 8
H-index: 2
I10-index:
Year
Topic
Type